Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
90.12
+2.49 (2.84%)
At close: Feb 25, 2026, 4:00 PM EST
90.12
0.00 (0.00%)
After-hours: Feb 25, 2026, 4:00 PM EST
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $400.00K in the quarter ending September 30, 2025, a decrease of -92.54%. This brings the company's revenue in the last twelve months to $18.97M, up 62.04% year-over-year. In the year 2024, Sol-Gel Technologies had annual revenue of $11.54M with 642.47% growth.
Revenue (ttm)
$18.97M
Revenue Growth
+62.04%
P/S Ratio
13.38
Revenue / Employee
$557,941
Employees
34
Market Cap
251.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
| Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
| Dec 31, 2017 | 174.00K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Silence Therapeutics | 25.83M |
| MediWound | 20.93M |
| Opus Genetics | 14.63M |
| Prelude Therapeutics | 10.50M |
| Camp4 Therapeutics | 3.80M |
| Surrozen | 3.60M |
| Inhibikase Therapeutics | 1.00 |
SLGL News
- 3 months ago - Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 9 months ago - Sol-Gel Reports First Quarter 2025 Results - GlobeNewsWire
- 10 months ago - Sol-Gel Announces Reverse Share Split - GlobeNewsWire
- 11 months ago - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - GlobeNewsWire
- 11 months ago - Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis - GlobeNewsWire
- 1 year ago - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire